Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design

Key facts

Study ID

NCT01302938

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

18

Starts

2011-03-01

Expected to finish

2012-08-01

Last updated by the study team

2021-01-28

Who can join

Age: 21 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female and 21 years or older
• Overactive bladder symptoms (subject-reported) for at least 3 months
• Be resident in the United States of America and have access and be able to use a computer with internet access throughout the duration of the study

You may not qualify if…

• Clinically significant hepatic, renal or neurological condition such as stroke (with residual deficit), multiple sclerosis, spinal cord injury, or Parkinson's disease.
• History of cystitis, continence, urogenitalcancer or radiation
• Subjects who are pregnant, nursing, or with a positive urine pregnancy test or who are intending to become pregnant within 28 days after the completion of the trial.

Where it is running

• Mytrus, Inc. — San Francisco, California, United States
• University of California San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.